A cohort study of p27 localization in colon cancer, body mass index, and patient survival

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 6, 2009, Pages 1849-1858

  Ogino, Shuji ^a,b,c   Shima, Kaori ^a   Nosho, Katsuhiko ^a   Irahara, Natsumi ^a   Baba, Yoshifumi ^a   Wolpin, Brian M ^a   Giovannucci, Edward L ^b,c   Meyerhardt, Jeffrey A ^a   Fuchs, Charles S ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLOOXYGENASE 2; FATTY ACID SYNTHASE; PROTEIN P27; PROTEIN P53;

AGED; ARTICLE; BODY MASS; CANCER SURVIVAL; CELL CYCLE PROGRESSION; COLON CANCER; CONTROLLED STUDY; CPG ISLAND; FEMALE; GENE LOCATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MUTATION; OBESITY; PRIORITY JOURNAL;

AGED; BODY MASS INDEX; COHORT STUDIES; COLONIC NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; NEOPLASM STAGING; OBESITY; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 67449103228     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0181     Document Type: Article

References (54)

1. Hursting SD, Nunez NP, Patel AC, Perkins SN, Lubet RA, Barrett JC. The utility of genetically altered mouse models for nutrition and cancer chemoprevention research. Mutat Res 2005;576:80-92. (Pubitemid 40982684)
2. Gunter MJ, Leitzmann MF. Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J Nutr Biochem 2006;17:145-156 (Pubitemid 43247408)
3. Haydon AM, Macinnis RJ, English DR, Giles GG. Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut 2006;55:62-67 (Pubitemid 41820637)
4. Dignam JJ, Polite BN, Yothers G, et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst 2006;98:1647-1654 (Pubitemid 44811647)
5. Abukhdeir AM, Park BH. P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med 2008;10:e19. (Pubitemid 351973866)
6. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-1274 (Pubitemid 46962095)
7. Medema R, Kops G, Bos J, Burgering B. AFX-like forkhead transcription mediate cell-cycle regulation by Ras and PKB through p27/kip1. Nature 2000;404:782-787 (Pubitemid 30212408)
8. von Harsdorf R, Hauck L, Mehrhof F, Wegenka U, Cardoso MC, Dietz R. E2F-1 overexpression in cardiomyocytes induces downregulation of p21CIP1 and p27KIP1 and release of active cyclin-dependent kinases in the presence of insulin-like growth factor I. Circ Res 1999;85:128-136 (Pubitemid 29343311)
9. Zhu Z, Jiang W, Thompson HJ. Mechanisms by which energy restriction inhibits rat mammary carcinogenesis: in vivo effects of corticosterone on cell cycle machinery in mammary carcinomas. Carcinogenesis 2003;24:1225-1231 (Pubitemid 36927063)
10. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008;8:253-267
11. Shapira M, Ben-Izhak O, Linn S, Futerman B, Minkov I, Hershko DD. The prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in colorectal carcinoma. Cancer 2005;103:1336-1346 (Pubitemid 40410727)
12. Belluco C, Esposito G, Bertorelle R, et al. Absence of the cell cycle inhibitor p27Kip1 protein predicts poor outcome in patients with stage I-III colorectal cancer. Ann Surg Oncol 1999;6:19-25. (Pubitemid 29077484)
13. Palmqvist R, Stenling R, Oberg A, Landberg G. Prognostic significance of p27(Kip1) expression in colorectal cancer: a clinico-pathological characterization. J Pathol 1999;188:18-23. (Pubitemid 29197309)
14. Tenjo T, Toyoda M, Okuda J, et al. Prognostic significance of p27(kip1) protein expression and spontaneous apoptosis in patients with colorectal adenocarcinomas. Oncology 2000;58:45-51. (Pubitemid 30045309)
15. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-234 (Pubitemid 27064711)
16. Noguchi T, Kikuchi R, Ono K, Takeno S, Moriyama H, Uchida Y. Prognostic significance of p27/kip1 and apoptosis in patients with colorectal carcinoma. Oncol Rep 2003;10:827-831
17. Galizia G, Lieto E, Ferraraccio F, et al. Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin Cancer Res 2004;10:3490-3499 (Pubitemid 38685457)
18. Li M, Li JY, Zhao AL, et al. Survival stratification panel of colorectal carcinoma with combined expression of carcinoembryonic antigen, matrix metalloproteinases-2, and p27 kip1. Dis Colon Rectum 2007;50:1887-1898 (Pubitemid 350077111)
19. Manne U, Jhala NC, Jones J, et al. Prognostic significance of p27(kip-1) expression in colorectal adenocarcinomas is associated with tumor stage. Clin Cancer Res 2004;10:1743-1752 (Pubitemid 38435566)
20. McKay JA, Douglas JJ, Ross VG, et al. Analysis of key cell-cycle checkpoint proteins in colorectal tumours. J Pathol 2002;196:386-393 (Pubitemid 34262849)
21. Tornillo L, Lugli A, Zlobec I, et al. Prognostic value of cell cycle and apoptosis regulatory proteins in mismatch repair-proficient colorectal cancer: a tissue microarray-based approach. Am J Clin Pathol 2007;127:114-123 (Pubitemid 46797026)
22. Cohen T, Prus D, Shia J, et al. Expression of P53, P27 and KI-67 in colorectal cancer patients of various ethnic origins: clinical and tissue microarray based analysis. J Surg Oncol 2008;97:416-422
23. Lyall MS, Dundas SR, Curran S, Murray GI. Profiling markers of prognosis in colorectal cancer. Clin Cancer Res 2006;12:1184-1191 (Pubitemid 43342507)
24. Wu JT, Kakar S, Nelson RL, et al. Prognostic significance of DCC and p27Kip1 in colorectal cancer. Appl Immunohistochem Mol Morphol 2005;13:45-54. (Pubitemid 40283802)
25. Rosati G, Chiacchio R, Reggiardo G, De Sanctis D, Manzione L. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival. Tumour Biol 2004;25:258-263
26. Prall F, Ostwald C, Nizze H, Barten M. Expression profiling of colorectal carcinomas using tissue microarrays: cell cycle regulatory proteins p21, p27, and p53 as immunohistochemical prognostic markers in univariate and multivariate analysis. Appl Immunohistochem Mol Morphol 2004;12:111-121 (Pubitemid 38788759)
27. Leopoldo S, Lorena B, Cinzia A, et al. Two subtypes of mucinous adenocarcinoma of the colorectum: clinicopathological and genetic features. Ann Surg Oncol 2008;15:1429-1439
28. Sarli L, Bottarelli L, Azzoni C, et al. Loss of p27 expression and microsatellite instability in sporadic colorectal cancer. Surg Oncol 2006;15:97-106. (Pubitemid 44802810)
29. Watson NF, Durrant LG, Scholefield JH, et al. Cytoplasmic expression of p27(kip1) is associated with a favourable prognosis in colorectal cancer patients. World J Gastroenterol 2006;12:6299-6304 (Pubitemid 44712410)
30. Zlobec I, Baker K, Terracciano LM, Lugli A. RHAMM, p21 combined phenotype identifies microsatellite instability-high colorectal cancers with a highly adverse prognosis. Clin Cancer Res 2008;14:3798-3806
31. Zlobec I, Minoo P, Baumhoer D, et al. Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer. Cancer 2008;112:495-502. (Pubitemid 351186190)
32. Ogino S, Kawasaki T, Kirkner GJ, Yamaji T, Loda M, Fuchs CS. Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP. Mod Pathol 2007;20:15-22. (Pubitemid 44967945)
33. Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS. Cytoplasmic localization of p27 (cyclin-dependent kinase inhibitor 1B/KIP1) in colorectal cancer: inverse correlations with nuclear p27 loss, microsatellite instability, and CpG island methylator phenotype. Hum Pathol 2007;38:585-592 (Pubitemid 46399885)
34. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90-96
35. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007;356:2131-2142 (Pubitemid 47010839)
36. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 2005;7:413-421 (Pubitemid 41149657)
37. Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn 2006;8:582-588 (Pubitemid 44774157)
38. Nosho K, Kawasaki T, Ohnishi M, et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 2008;10:534-541 (Pubitemid 351770297)
39. Ogino S, Brahmandam M, Cantor M, et al. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol 2006;19:59-68. (Pubitemid 43250979)
40. Ogino S, Kawasaki T, Brahmandam M, et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006;8:209-217 (Pubitemid 43811244)
41. Ogino S, Cantor M, Kawasaki T, et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 2006;55:1000-1006 (Pubitemid 43962613)
42. Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. JMol Diagn 2007;9:305-314 (Pubitemid 47305066)
43. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006;38:787-793 (Pubitemid 43980599)
44. Nosho K, Irahara N, Shima K, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS ONE 2008;3:e3698.
45. Ogino S, Kawasaki T, Nosho K, et al. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG methylator phenotype in colorectal cancer. Int J Cancer 2008;122:2767-2773 (Pubitemid 351631379)
46. Ogino S, Nosho K, Kirkner GJ, et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst 2008;100:1734-1738
47. Nosho K, Kawasaki T, Chan AT, et al. Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype. Histopathology 2008;53:588-598
48. Kawasaki T, Nosho K, Ohnishi M, et al. Correlation of β-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. Neoplasia 2007;9:569-577 (Pubitemid 47121831)
49. Ogino S, Nosho K, Meyerhardt JA, et al. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol 2008;26:5713-5720
50. Ogino S, Meyerhardt JA, Cantor M, et al. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res 2005;11:6650-6656 (Pubitemid 41339006)
51. Grunau C, Brun ME, Rivals I, et al. BAGE hypomethylation, a new epigenetic biomarker for colon cancer detection. Cancer Epidemiol Biomarkers Prev 2008;17:1374-1379
52. Poynter JN, Siegmund KD, Weisenberger DJ, et al. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev 2008;17:3208-3215
53. English DR, Young JP, Simpson JA, et al. Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype. Cancer Epidemiol Biomarkers Prev 2008;17:1774-1780
54. Weinstein SJ, Albanes D, Selhub J, et al. One-carbon metabolism biomarkers and risk of colon and rectal cancers. Cancer Epidemiol Biomarkers Prev 2008;17:3233-3240